Company Profile

Checkpoint Therapeutics is committed to advancing the development of cancer immunotherapy and targeted oncology treatments and creating accessible, effective and potentially more affordable options for patients everywhere.

Along with our leading candidates cosibelimab and olafertinib, we are dedicated to developing and bringing cancer therapies to market faster and actively pursuing product purchases, in-licensing and co-development opportunities that align with our areas of expertise, offering better patient outcomes and delivering significant value to the future of healthcare.

Latest Presentation

Corporate Presentation

View This Presentation

Industry Classifications



Research and Development in Biotechnology (except Nanobiotechnology) (541714)

Commercial Physical and Biological Research (8731)

Contact Information

Investor Relations
LifeSci Advisors, LLC
Ashley R. Robinson
Managing Director
T: 617-430-7577

Company Contact
Checkpoint Therapeutics, Inc.
95 Sawyer Road
Suite 110
Waltham, MA 02453
T: 781-652-4500
F: 646-619-4950